Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ananth Vellimana

Neurological Surgery Saint Louis, MO Medical Doctor

NPI 1144583113 CMS profile 1050752

4921 Parkview Pl, Div Neurological Surgery, Ste 6B/6C, Saint Louis, MO 63110

Open in the dashboard

General payments

$28,282

91 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12,420 paid to institutions, not to them · program year 2025

Through program year 2025, Ananth Vellimana of Saint Louis, MO is reported in the CMS Open Payments database as having received $28,282 across 91 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $12,420 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 81st percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,882 21
2024 General $7,217 13
2023 General $5,074 20
2022 General $3,095 6
2021 General $2,372 15
2020 General $1,541 14
2019 General $100 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ananth Vellimana
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Ananth Vellimana were reported at $8,882. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Ananth Vellimana Neurological Surgery median Middle half National median
2019 $100 $582 $138–$3,006 $163
2020 $1,541 $294 $76–$2,174 $114
2021 $2,372 $387 $105–$2,432 $132
2022 $3,095 $542 $139–$2,989 $149
2023 $5,074 $534 $145–$2,697 $160
2024 $7,217 $574 $155–$3,046 $164
2025 $8,882 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $14,997 32 payments
  2. Medical Device Business Services, Inc. $8,854 19 payments
  3. Aesculap, Inc. $1,396 13 payments
  4. Stryker Corporation $1,217 3 payments
  5. Silk Road Medical, Inc. $639 6 payments
  6. Medtronic, Inc. $388 6 payments
  7. Integra LifeSciences Corporation $339 6 payments
  8. DePuy Synthes Sales Inc. $145 1 payment
  9. Route 92 Medical, Inc. $134 2 payments
  10. Balt USA, LLC $115 1 payment
  11. Other $58 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $10,331 27 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,600 4 payments
  3. Consulting Fee $4,500 1 payment
  4. Food and Beverage $3,851 59 payments
Products named General payments · program years 2019–2025
  1. Penumbra System $14,644 23 payments
  2. EMBOGUARD $6,000 2 payments
  3. CEREPAK UNIFORM $1,488 12 payments
  4. YASARGIL ANEURYSM CLIPS $1,396 13 payments
  5. TRUFILL $1,367 5 payments
  6. Pulsar Vascular PulseRider Aneurysm Neck Reconstruction Device $1,367 5 payments
  7. EVOLVE $1,217 3 payments
  8. ENROUTE Transcarotid Neuroprotection System $639 6 payments
  9. ENROUTE Transcarotid Stent $639 6 payments
  10. ENHANCE Transcarotid Peripheral Access Kit $639 6 payments
  11. Other $3,430 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

191

Median for Neurosurgery: 83

Drug cost

$20,978

Median for Neurosurgery: $872

Branded share of claims

42.9%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 41 $19,393
Carbamazepine Generic 27 $577
Levetiracetam Generic 16 $331
Gabapentin Generic 25 $323
Mupirocin Generic 24 $159
Clopidogrel Clopidogrel Bisulfate Brand 41 $107
Topiramate Generic 17 $89

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$179,445

Medicare's payments for the services billed

Medicare patients

261

Average age 72

Services billed

1,097

143 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 43%
Depression 36%
Chronic kidney disease 35%
Diabetes 32%
Heart failure 29%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record